Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia
Status:
Withdrawn
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Recombinant Human Interleukin-11 (rhIL-11)
Combination Low-dose Rituximab prednisone are effective and safe in the management of
Steroid-Resistant/Relapsed Immune Thrombocytopenia (ITP).
Details
Lead Sponsor:
Ming Hou
Collaborators:
Chinese Academy of Medical Sciences First Affiliated Hospital, Sun Yat-Sen University Peking Union Medical College Hospital Shandong Provincial Hospital West China Hospital Wuhan Union Hospital, China Zhejiang University